Sandbox:Mitra3: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 14: | Line 14: | ||
• '''In patients with hypotension (without pulmonary congestion): | • '''In patients with hypotension (without pulmonary congestion): | ||
:❑ Intravenous administration of Fluids (N/S 0.9% at 40mL for 2L, to maintain CVP <15mmHg and PCWP between 18-24 mmHg) | :❑ Intravenous administration of Fluids (N/S 0.9% at 40mL for 2L, to maintain CVP <15mmHg and PCWP between 18-24 mmHg) | ||
|C03=• '''Systemic or pulmonary vasodilators:'''<br> | |C03=<div style="float: Center; text-align: left;"> • '''Systemic or pulmonary vasodilators:'''<br> | ||
:❑Nitrosrusside | :❑Nitrosrusside | ||
:❑Inhaled nitric oxide<be> | :❑Inhaled nitric oxide<be> | ||
|C04=• '''In patients with bradyarrhthmias:'''<br> | |C04=<div style="float: Center; text-align: left;"> • '''In patients with bradyarrhthmias:'''<br> | ||
:❑Atropine | :❑Atropine | ||
:❑Pacemaker | :❑Pacemaker | ||
• '''In patients with atrioventricular block:'''<br> | • '''In patients with atrioventricular block:'''<br> | ||
:❑Temporary dual-chamber pacemaker | :❑Temporary dual-chamber pacemaker | ||
|C05= | |C05=<div style="float: Center; text-align: left;"> '''In patients with refractory hypotension:'''<br> | ||
:❑Dobutamine (along with fluids) | :❑Dobutamine (along with fluids) | ||
:❑Other inotropes: | :❑Other inotropes: | ||
*milrinone | *milrinone | ||
*norepinephrine | *norepinephrine | ||
|C06= May be needed in patients with cardiogenic shock secondary to RVMI: | |C06= <div style="float: Center; text-align: left;"> • '''May be needed in patients with cardiogenic shock secondary to RVMI''': | ||
:❑Direct RV support | :❑Direct RV support | ||
:❑Indirect RV support | :❑Indirect RV support | ||
Revision as of 18:15, 3 August 2020
Therapuetic Considerations in RVMI | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reperfusion | Maintenance of RV preload | Decreased RV afterload | Restoring Rate/Rhythm and AV synchrony | Inotropic support | Mechanical Circulatory Support | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
•Thrmobolytics •Percutaneous coronary intervention (PCI) | • Avoidance of preload reducing agents, such as:
• In patients with hypotension (without pulmonary congestion):
| • Systemic or pulmonary vasodilators: | • In patients with bradyarrhthmias: • In patients with atrioventricular block:
| In patients with refractory hypotension:
| • May be needed in patients with cardiogenic shock secondary to RVMI:
| {{{ }}} | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||